Skip to content
Psilocybin Research

Psilocybin compared with the other psychedelics

The evidenceReviewed

The one distinction that matters

Comparison tables of these compounds usually give each one a hopeful sentence, which makes the differences look cosmetic. They are not cosmetic. One of these is an approved medicine your doctor can prescribe today. One has been formally rejected by the FDA and is on its second attempt. One has caused deaths.

The useful column is not whether something “shows promise” — everything in development shows promise, by definition, or it would not be in development. The useful column is what a regulator has actually concluded, because that is what determines whether you can obtain it, whether anyone is accountable for how it is given to you, and whether insurance will pay.

At a glance

The four questions, answered across all six

Ordered by regulatory status rather than by interest, because that is the order that affects what you can actually do. Durations are typical ranges — they vary with dose, route and person.

Psilocybin compared with esketamine, ketamine, MDMA, LSD and ibogaine on regulatory status, lawful access, session length and controlled-substance schedule.
CompoundWhat the FDA has decidedCan you get it todayHow long it lastsSchedule
EsketamineSpravatoFDA approvedOn prescriptionAbout 40 minutesSchedule III
Ketamineracemic, usually IVFDA approvedOn prescriptionAbout 40 minutesSchedule III
PsilocybinApplication expectedTwo states onlyFour to six hoursSchedule I
MDMARejected once, refiledTrials onlyThree to six hoursSchedule I
LSDInvestigational onlyTrials onlyEight to twelve hoursSchedule I
IbogaineInvestigational onlyNo lawful routeTwenty-four to thirty-six hoursSchedule I

Two of these are prescribable today and four are not, and that single division does more to determine what happens to you than any difference in the evidence. It is also the division most comparison tables in this category leave out.

In detail

Where each one stands

The same six, with what a regulator concluded, where the evidence sits, and the part a promotional page would leave out.

Esketamine(Spravato)

FDA approvedSchedule III

What the FDA has done
Approved by the FDA in 2019 for treatment-resistant depression, and in 2020 for depressive symptoms in adults with major depressive disorder and acute suicidal ideation or behavior.
Where the evidence stands
The only compound in this comparison that has cleared the FDA's evidentiary bar for a psychiatric indication. That is a statement about regulatory status, not about it being the most effective option for any given person.
What you can legally access
By prescription, administered under supervision at a REMS-certified clinic. Often at least partly covered by insurance, because it is approved.
What a session involves
Self-administered nasal spray at a REMS-certified clinic, then at least two hours of monitoring before you may leave. You cannot drive afterwards.
What gets left out
Approval is why it is frequently cheaper to the patient than psilocybin despite costing no less to deliver. Coverage follows approval.

Ketamine(racemic, usually IV)

FDA approvedSchedule III

What the FDA has done
Approved as an anesthetic. Its use for depression is off-label, which means legal and prescribable but not FDA-evaluated for that purpose.
Where the evidence stands
A substantial literature on rapid, short-lived antidepressant effects. Off-label status means no regulator has assessed the depression evidence to an approval standard, and the infusion-clinic sector is very lightly regulated.
What you can legally access
Widely available at private infusion clinics. Rarely covered by insurance.
What a session involves
Usually an IV infusion at a private clinic with monitoring during and briefly after. Protocols vary widely between clinics because almost nothing about them is standardized.
What gets left out
Off-label is not the same as unapproved, and neither is the same as evaluated. The three get conflated constantly in marketing.

Psilocybin

Application expectedSchedule I

What the FDA has done
Not approved. Compass Pathways reported positive results from two late-stage COMP360 trials and said in February 2026 that it expected to submit an application between October and December 2026. No submission has been confirmed.
Where the evidence stands
The largest evidence base of the unapproved compounds here, and the most misreported. Two Phase 3 trials met their primary endpoints with modest differences of 3.6 and 3.8 MADRS points. The most-quoted trial in the field — psilocybin against escitalopram — did not meet its primary endpoint.
What you can legally access
No prescription route anywhere in the US. Supervised non-medical access in Oregon and Colorado under state programs, paid entirely out of pocket. Clinical trials elsewhere.
What a session involves
A supervised session of six to eight hours with a trained facilitator present throughout, wrapped in preparation beforehand and integration afterwards. That day of staff time is most of what it costs.
What gets left out
State legal access is not medical approval, and the two are routinely described as though they were the same thing.

MDMA

Rejected once, refiledSchedule I

What the FDA has done
Rejected. The FDA issued a Complete Response Letter on 9 August 2024, citing treatment durability, safety characterization and bias. Resilient Pharmaceuticals announced a resubmission on 9 August 2026 — without a new Phase 3 study.
Where the evidence stands
The most advanced psychedelic program to reach the FDA, and the one that shows what that bar means. The trials were not judged sufficient the first time, largely over functional unblinding and how therapy effects were separated from drug effects — problems the whole field shares.
What you can legally access
None outside clinical trials.
What a session involves
Eight-hour supervised sessions with two therapists present, in the trial protocol that the FDA declined to approve.
What gets left out
MDMA is widely marketed for PTSD as though approval were imminent. It has been formally rejected once, and the resubmission rests on the same trial data.

LSD

Investigational onlySchedule I

What the FDA has done
Not approved for any indication. In clinical development for anxiety disorders.
Where the evidence stands
A smaller and more recent clinical literature than psilocybin's, concentrated in generalized anxiety rather than depression. Nothing has reached a regulatory decision.
What you can legally access
None outside clinical trials.
What a session involves
A full day, which is the practical reason it is harder to deliver as a supervised therapy than psilocybin even where the evidence is comparable.
What gets left out
Longer duration than psilocybin — commonly eight to twelve hours — which is a practical obstacle to delivering it as a supervised therapy at scale.

Ibogaine

Investigational onlySchedule I

What the FDA has done
Not approved. No completed Phase 3 program in the US.
Where the evidence stands
Observational reports in opioid use disorder, largely from unregulated clinics abroad, with no adequately controlled trial to draw on. Several US states have funded research since 2025.
What you can legally access
None legally in the US. People travel to clinics in Mexico and elsewhere, which operate outside any regulatory oversight.
What a session involves
Requires continuous cardiac monitoring. The clinics people actually travel to are unregulated, and monitoring is exactly what is missing where deaths have occurred.
What gets left out
The serious one. Ibogaine prolongs the QT interval and has caused fatal cardiac arrhythmias. Deaths are documented at unregulated clinics. It does not belong in a list of compounds discussed purely in terms of promise, which is where it usually appears.

Questions people ask

Which psychedelic is FDA approved?
Esketamine (Spravato) is approved for treatment-resistant depression and for depressive symptoms with acute suicidal ideation. Ketamine is approved as an anesthetic and used off-label for depression, which is legal and prescribable but has not been FDA-evaluated for that use. Psilocybin, MDMA, LSD and ibogaine have no FDA approval for any psychiatric indication.
Is MDMA approved for PTSD?
No. The FDA issued a Complete Response Letter rejecting the application on 9 August 2024, citing treatment durability, safety characterization and bias in the trials. Resilient Pharmaceuticals announced a resubmission on 9 August 2026, without a new Phase 3 study. MDMA is widely marketed for PTSD as though approval were imminent; it has been formally rejected once and the refiling rests on the same data.
Is psilocybin or ketamine more effective for depression?
There is no good head-to-head answer, and anyone giving you a confident one is going beyond the evidence. They have not been compared in an adequately powered trial. What can be said is that esketamine has cleared the FDA's bar for treatment-resistant depression and psilocybin has not yet been submitted, and that ketamine's effects are rapid but short-lived while psilocybin's are claimed to be durable on the basis of smaller and shorter follow-up.
Is ibogaine safe?
Ibogaine prolongs the QT interval and has caused fatal cardiac arrhythmias. Deaths are documented at unregulated clinics abroad, which is where nearly all ibogaine administration happens, since it is Schedule I in the US with no approved use. It is frequently discussed alongside psilocybin and MDMA in terms of promise alone, and its risk profile is not comparable to theirs.

For psilocybin specifically, see what the evidence shows, how far away approval is and what it costs against the approved alternatives.